ArticleCureus2026
Upadacitinib for Refractory Anti-melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis-Related Interstitial Lung Disease.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a 54-year-old man with recurrent anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis (DM)-associated interstitial lung disease (ILD) who was refractory to intensive triple therapy with high-dose glucocorticoids, tacrolimus, and intravenous cyclophosphamide. After relapse following treatment discontinuation, he developed worsening respiratory symptoms, elevated ferritin and Krebs von den Lungen-6 (KL-6) levels, and progressive ILD on computed tomography. Despite the reintroduction of triple therapy, his condition deteriorated. Upadacitinib was initiated at 15 mg/day and later escalated to 30 mg/day. Subsequently, respiratory symptoms improved, oxygen therapy was discontinued, inflammatory biomarkers declined, and radiologic findings markedly improved. Infectious complications, including bacteremia, cellulitis, and cytomegalovirus reactivation, were successfully managed with close monitoring. This case suggests that upadacitinib may be an effective add-on therapy for refractory anti-MDA5 antibody-positive DM-associated ILD when conventional intensive treatment is insufficient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.